Stock Scorecard
Stock Summary for Abbott Laboratories (ABT) - $125.12 as of 12/19/2025 5:40:57 PM EST
Total Score
12 out of 30
Safety Score
45 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ABT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ABT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ABT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ABT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ABT (45 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 7 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 4 |
| Operating Margin (Max of 10) | 4 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for ABT
Financial Details for ABT
Company Overview |
|
|---|---|
| Ticker | ABT |
| Company Name | Abbott Laboratories |
| Country | N/A |
| Description | Abbott Laboratories (ABT) is a prominent American multinational healthcare company based in Abbott Park, Illinois, with expertise across a diverse range of sectors, including medical devices, diagnostics, nutritional products, and branded generic medicines. Established in 1888, Abbott has demonstrated a strong commitment to innovation, enhancing health outcomes through cutting-edge technology and comprehensive healthcare solutions. The company's strategic decision to spin off its research-based pharmaceutical operations into AbbVie in 2013 has allowed it to focus on its core offerings while maintaining a legacy of excellence in healthcare. With a robust global presence, Abbott is well-positioned to capitalize on emerging market opportunities and address evolving healthcare needs. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 1/28/2026 |
Stock Price History |
|
| Last Day Price | 125.12 |
| Price 4 Years Ago | 130.53 |
| Last Day Price Updated | 12/19/2025 5:40:57 PM EST |
| Last Day Volume | 5,891,883 |
| Average Daily Volume | 6,418,246 |
| 52-Week High | 139.33 |
| 52-Week Low | 109.21 |
| Last Price to 52 Week Low | 14.57% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 41.90 |
| Sector PE | 53.39 |
| 5-Year Average PE | 25.72 |
| Free Cash Flow Ratio | 28.96 |
| Industry Free Cash Flow Ratio | 28.74 |
| Sector Free Cash Flow Ratio | 33.77 |
| Current Ratio Most Recent Quarter | 1.70 |
| Total Cash Per Share | 4.32 |
| Book Value Per Share Most Recent Quarter | 29.30 |
| Price to Book Ratio | 4.18 |
| Industry Price to Book Ratio | 4.40 |
| Sector Price to Book Ratio | 49.15 |
| Price to Sales Ratio Twelve Trailing Months | 4.89 |
| Industry Price to Sales Ratio Twelve Trailing Months | 7.19 |
| Sector Price to Sales Ratio Twelve Trailing Months | 14.97 |
| Analyst Buy Ratings | 15 |
| Analyst Strong Buy Ratings | 6 |
Share Statistics |
|
| Total Shares Outstanding | 1,738,872,000 |
| Market Capitalization | 217,567,664,640 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 1/15/2026 |
| Previous Dividend Amount | 0.5900 |
| Current Dividend Amount | 0.6300 |
| Total Years Dividend Increasing |
|
| Trailing Annual Dividend Rate | 2.36 |
| Trailing Annual Dividend Yield | 1.86% |
| Forward Annual Dividend Rate | 2.52 |
| Forward Annual Dividend Yield | 1.99% |
| 5-Year Dividend Payments Count | 21 |
| 3-Year Average Dividend Yield | 2.00% |
| 5-Year Average Dividend Yield | 1.82% |
| 1-Year Dividend Growth Rate Percentage | 14.55% |
| 3-Year Dividend Growth Rate Percentage | 7.03% |
| 5-Year Dividend Growth Rate Percentage | 8.78% |
| All-Time Dividend Growth Rate Percentage | 8.42% |
| Dividend Payout Ratio | 29.46% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 134.18% |
| Reported EPS 12 Trailing Months | 8.01 |
| Reported EPS Past Year | 3.07 |
| Reported EPS Prior Year | 4.67 |
| Net Income Twelve Trailing Months | 13,977,000,000 |
| Net Income Past Year | 13,402,000,000 |
| Net Income Prior Year | 5,723,000,000 |
| Quarterly Revenue Growth YOY | 6.90% |
| 5-Year Revenue Growth | 5.63% |
| Operating Margin Twelve Trailing Months | 19.40% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 7,511,000,000 |
| Total Cash Past Year | 7,616,000,000 |
| Total Cash Prior Year | 6,896,000,000 |
| Net Cash Position Most Recent Quarter | -4,085,000,000 |
| Net Cash Position Past Year | -5,009,000,000 |
| Long Term Debt Past Year | 12,625,000,000 |
| Long Term Debt Prior Year | 13,599,000,000 |
| Total Debt Most Recent Quarter | 11,596,000,000 |
| Equity to Debt Ratio Past Year | 0.79 |
| Equity to Debt Ratio Most Recent Quarter | 0.81 |
| Total Stockholder Equity Past Year | 47,664,000,000 |
| Total Stockholder Equity Prior Year | 38,603,000,000 |
| Total Stockholder Equity Most Recent Quarter | 50,954,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 6,917,000,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 3.98 |
| Free Cash Flow Past Year | 6,351,000,000 |
| Free Cash Flow Prior Year | 5,059,000,000 |
Options |
|
| Put/Call Ratio | 0.19 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.71 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 109.84 |
System |
|
| Modified | 12/19/2025 4:19:19 PM EST |